|1.||Braida, D: 3 articles (01/2001 - 06/2000)|
|2.||Sala, M: 3 articles (01/2001 - 06/2000)|
|3.||Imbimbo, B P: 2 articles (01/2001 - 01/2000)|
|4.||Sailas, Eila: 1 article (11/2004)|
|5.||Soares-Weiser, Karla: 1 article (11/2004)|
|6.||Wahlbeck, Kristian: 1 article (11/2004)|
|7.||McGrath, John J: 1 article (11/2004)|
|8.||Tammenmaa, Irina A: 1 article (11/2004)|
|9.||Liston, Dane R: 1 article (02/2004)|
|10.||Shalaby, Ismail A: 1 article (02/2004)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2001 - "Clinical investigations on more than 1500 patients with Alzheimer's disease demonstrated that eptastigmine significantly improved cognitive performance (as assessed by the cognitive subscale of the Alzheimer's Disease Assessment Scale) as compared with placebo. "
01/01/2000 - "A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease."
03/01/1999 - "This study indicates that prolonged treatment with eptastigmine is safe and produced a clinically long-term benefit in patients with Alzheimer's disease."
03/01/1999 - "We evaluated the effects of prolonged treatment with eptastigmine in 176 patients with mild to moderate Alzheimer's disease participating in the open-label extension phase of a 25-week double-blind, placebo-controlled trial of eptastigmine. "
12/01/1998 - "The efficacy and safety of eptastigmine in patients with probable Alzheimer disease was evaluated in a double-blind, placebo-controlled, parallel group study. "
|2.||Movement Disorders (Movement Disorder)
11/01/2004 - "The authors evaluated the efficacy of cholinergic drugs in the treatment of neuroleptic-induced tardive dyskinesia (TD) by a systematic review of the literature on the following agents: choline, lecithin, physostigmine, tacrine, 7-methoxyacridine, ipidacrine, galantamine, donepezil, rivastigmine, eptastigmine, metrifonate, arecoline, RS 86, xanomeline, cevimeline, deanol, and meclofenoxate. "
01/01/2002 - "To determine the effects of cholinergic drugs (arecoline, choline, deanol, lecithin, meclofenoxate, physostigmine, RS 86, tacrine, metoxytacrine, galantamine, ipidacrine, donepezil, rivastigmine, eptastigmine, metrifonate, xanomeline, cevimeline) for treating neuroleptic-induced tardive dyskinesia in people with schizophrenia or other chronic mental illness. "
|3.||Memory Disorders (Memory Loss)
10/01/2000 - "Eptastigmine, a potent and long-lasting cholinesterase inhibitor on age-related memory deficits, was studied. "
06/26/2000 - "20 min earlier, significantly reduced the memory deficit Pretreatment with eptastigmine, a second generation cholinesterase inhibitor, given orally 100 min before the cannabinoid agonist, relieved the memory impairment without affecting CP 55,940-induced behavioural alterations such as reduced spontaneous motor activity, analgesia and hind limb splaying. "
02/01/1992 - "Clinical trials with heptyl physostigmine will enable a more rigorous evaluation of cholinomimetic therapy for dementia."
12/01/1998 - "Patients with mild to moderate dementia were randomly assigned to placebo, eptastigmine 10 mg three times a day (t.i.d.), or eptastigmine 15 mg t.i.d. "
01/01/2001 - "For example, the incidence of nausea (in excess of that seen with placebo) at cognitively effective dosages ranges from 1% with eptastigmine 60 mg/day to 53% with physostigmine 30 mg/day. "
01/01/2000 - "Cholinergic side effects (nausea, vomiting, diarrhea and abdominal pain) were reported with similar frequency in the eptastigmine and placebo-treated patients. "
03/10/1999 - "Cholinergic side effects (nausea, vomiting, diarrhea, and abdominal pain) were reported with similar frequency in the eptastigmine- and placebo-treated patients. "
|6.||Cholinergic Agents (Cholinergics)
|10.||Choline (Choline Chloride)
|4.||Activities of Daily Living (ADL)